- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lindsey Roeker: Novel Agents Have Revolutionized CLL Treatment
The introduction of novel agents has really revolutionized the care of patients with chronic lymphocytic leukemia to the point where chemotherapy is rarely used, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
The introduction of novel agents has really revolutionized the care of patients with chronic lymphocytic leukemia to the point where chemotherapy is rarely used, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
Transcript
How has the introduction of novel agents changed treatment paradigms in CLL?
CLL is a radically different disease than it was in the era of chemotherapy. We pretty much don’t use chemotherapy at this point in our practice. It really has become a disease that’s managed with novel agents, and we’re figuring out how to most effectively sequence novel agents to make sure that’s a durable strategy. But, CLL has been revolutionized by those novel agents.
Have you seen outcomes and patient experiences change as a result of these novel agents?
As a trainee who has trained really in the era of novel agents, my exposure to chemotherapy for CLL is rather limited, to be honest. So, the few patients that we have treated with chemo just have a different side effect profile and a much higher toxicity burden. For most patients these novel agents are really pretty well tolerated, and we’re able to manage side effects and really have people have durable time on these novel agents.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
